Long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Heidelberg, Universität Heidelberg, Dissertation, 2024
- Keyword
-
gastric cancer
trastuzumab
HER2
next-generation sequencing
PD-L1
- Event
-
Veröffentlichung
- (where)
-
Heidelberg
- (who)
-
Universitätsbibliothek Heidelberg
- (when)
-
2024
- Creator
- Contributor
- DOI
-
10.11588/heidok.00034645
- URN
-
urn:nbn:de:bsz:16-heidok-346459
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Porth, Isabel
- Gaiser, Timo
- Universitätsbibliothek Heidelberg
Time of origin
- 2024
Other Objects (12)
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma : Past, present and future
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma : Past, present and future
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma : Past, present and future
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer